COL7A1 and epidermolysis bullosa: Most efforts to develop gene editing–based therapies for EB have focused on the correction of RDEB or DDEB mutations in COL7A1,86, 87, 88, 89, 90, 91, 92, 93, 94, whereas JEB (LAMA395 and LAMB396) and EBS (KRT597, KRT1498) were less frequently reported.